ESTABLISHMENT AND PRODUCT APPLICATIONS FOR LICENSE FOR THE MANUFACTURE OF BIOLOGICAL ALLERGENIC AND PLASMA DERIVATIVE PRODUCTS, BLOOD AND BLOOD COMPONENTS
ICR 199009-0910-003 · OMB 0910-0124 · Historical Active
⚠️ Notice: This information collection may be outdated. More recent filings for OMB 0910-0124 can be found here:
ESTABLISHMENT AND PRODUCT APPLICATIONS FOR LICENSE FOR THE MANUFACTURE OF BIOLOGICAL ALLERGENIC AND PLASMA DERIVATIVE PRODUCTS, BLOOD AND BLOOD COMPONENTS
Reinstatement with change of a previously approved collection
This information collection is approved for use until May 31, 1992. In its next submission, FDA should explain its progress toward the computerization of the submission of licensing information and an evaluation of the effect improved technology would have on reporting and recordkeeping burdens.
Inventory as of this Action
Requested
Previously Approved
05/31/1992
05/31/1992
1,113
0
0
83,661
0
0
0
0
0
SECTION 351, PHS ACT AND 21 CFR 601.2 REQUIRES ALL MANUFACTURERS OF BIOLOGICAL PRODUCTS TO SUBM APPLICATIONS FOR REVIEW AND APPROVAL TO FDA PRIOR TO MARKETING A PRODUCT. A SEPARATE LICENSE IS ISSUED TO THE MANUFACTURER FOR EACH APPROVED PRODUCT APPLICATION. THE DATA IS USED TO DETERMINE IF THE MANUFACTURER IS IN COMPLIANCE WITH LICENSE PROVISIONS OF THE
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.